Direct Skeletal Muscle Cell Reprogramming via MyoD and L-myc
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing skeletal muscle cells in humans are inefficient compared to mice, and existing approaches face challenges such as immunological rejection and carcinogenesis risks associated with pluripotent stem cells.
Innovation Solution
Direct reprogramming of mammalian somatic cells, specifically by introducing the MyoD1 gene and L-myc gene, bypasses the need for pluripotent stem cells and allows for the generation of skeletal muscle cells that can be used for transplantation without immunological rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MyoD family gene is introduced into human fibroblasts, then myoblast induction is attempted, but the induction efficiency is significantly lower compared to mouse fibroblasts
Solution Approach 1:
The invention changes the genetic parameters by introducing not only MyoD family gene but also Myc family gene (c-Myc, L-Myc, or N-Myc) into human fibroblasts. This combination of genetic factors overcomes the species-specific limitation and achieves efficient myoblast induction in human cells, resolving the contradiction between reliability and species-specific constraints
Solution Approach 2:
The invention uses a composite approach by combining multiple transcription factors (MyoD family + Myc family) to create a synergistic effect. This composite genetic intervention successfully induces myoblasts in human fibroblasts where single factor introduction failed, thereby improving induction efficiency while overcoming biological limitations
2Adaptability or versatility
If pluripotent stem cells (ES cells or iPS cells) are used for skeletal muscle cell generation, then cell proliferation and differentiation capacity is improved, but the risk of carcinogenesis and immunological rejection increases
Solution Approach 1:
The invention extracts and eliminates the problematic intermediate step of using pluripotent stem cells. By directly differentiating somatic cells into skeletal muscle cells through MyoD and Myc gene introduction, the method removes the carcinogenesis risk and immunological rejection issues associated with pluripotent stem cells while maintaining differentiation capacity
Solution Approach 2:
The invention skips the pluripotent stem cell stage entirely in the differentiation pathway. Instead of going through ES cells or iPS cells, the method directly converts somatic cells into skeletal muscle cells, thereby avoiding the harmful effects of pluripotency while achieving the desired cell type conversion
3Loss of time
If direct reprogramming method is used to generate skeletal muscle cells, then the induction time is reduced and safety is improved, but the complexity of gene introduction increases
Solution Approach 1:
The invention merges the functions of multiple genes (MyoD family + Myc family) into a coordinated introduction system. This combined approach achieves rapid and efficient direct reprogramming while managing the complexity through systematic gene delivery, resolving the trade-off between speed and complexity
Data Source
AI summary
Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.